North America Cardiovascular Therapeutic Drugs Market By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertension, Hyperlipidaemia, Thrombosis, Cardiac Failure Diseases And Other Cardiovascular Diseases), By Drug Class (monotherapies And Combination) And By Region – Industry Analysis, Size, Share, Growth, Trends, And Forecast (2018 – 2023)

North America Cardiovascular Therapeutic Drugs Market By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertension, Hyperlipidaemia, Thrombosis, Cardiac Failure Diseases And Other Cardiovascular Diseases), By Drug Class (monotherapies And Combination) And By Region – Industry Analysis, Size, Share, Growth, Trends, And Forecast (2018 – 2023)

ID: 1427 | Pages: 145 | April 2018 | Region: North America


North American Cardiovascular Therapeutic Drugs Market is estimated to be USD 51.65 billion in 2018 and is poised to reach USD 57.31 billion by 2023 growing at a CAGR of 2.1%. The past several decades have witnessed huge success in the development of effective drug therapies for common cardiovascular disease. These therapies have been widely used with the rising prevalence of cardiovascular diseases resulting in the increased market for cardiovascular therapeutics.

Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. Cardiovascular diseases are responsible for majority of the deaths globally and continues to cause health problems. These health problems mainly includes heart failure, blood clots, coronary artery disease, high cholesterol and others.

While cardiovascular disorders remains the major cause of morbidity and mortality in the world, the therapeutic drugs market is driven by the increasing aging population, epidemic of general medical problems like obesity & diabetes and growth in the per capita medical spending. However, shrinking target population, rising cost of drug development are the major restraint faced by the market. And, despite the wide prevalence of the cardiovascular diseases, pipelines for drug development products have been stagnant for variety of reasons.

North America cardiovascular therapeutic drug market is categorised on the basis of disease and drug class. On the basis of disease, the market is classified as cardiac arrhythmias, Arteriosclerosis, acute coronary syndrome, Myocardial infarction, Coronary artery disease, Peripheral artery disease, thrombosis, hyperlipidaemia, hypertension, cardiac failure diseases and others. On the basis of drug class the market is categorised as monotherapies and combination drug classes. On the basis of geography of North America, the market is segmented into United States and Canada.

The leading companies in the cardiovascular therapeutic drugs market includes AstraZeneca, Bayer, boehringer ingelheim, Bristol-Myers Squibb (BMS), Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi and Takeda.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease                  

                                5.1.1 Arteriosclerosis     

                                5.1.2 Cardiac arrhythmias            

                                5.1.3 Myocardial infarction         

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease  

                                5.1.6 Coronary artery disease    

                                5.1.7 Hypertension        

                                5.1.8 Hyperlipidaemia   

                                5.1.9 Thrombosis            

                                5.1.10 Cardiac failure diseases  

                                5.1.11 Others   

                5.2 By Drug Class                             

                                5.2.1 Monotherapies     

                                5.2.2 Combination Therapies     

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 United States                            

                6.3 Canada                         

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues            

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 Novartis                       

                9.3 Bristol-Myers Squibb                              

                9.4 Pfizer                            

                9.5 Sanofi                           

                9.6 Merck                           

                9.7 Bayer                            

                9.8 Takeda                         

                9.9 Boehringer Ingelheim                            

                9.10 Johnson & Johnson                              

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Cardiovascular Therapeutic Drugs Market By Region, From 2018-2023 (USD billion)                                                           
  2. North America Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                         
  3. North America Arteriosclerosis Market By Region, From 2018-2023 (USD billion)                                                               
  4. North America Cardiac arrhythmias Market By Region, From 2018-2023 (USD billion)                                                      
  5. North America Myocardial infarction Market By Region, From 2018-2023 (USD billion)                                                   
  6. North America Acute Coronary Syndrome Market By Region, From 2018-2023 (USD billion)                                                         
  7. North America Peripheral artery disease Market By Region, From 2018-2023 (USD billion)                                                            
  8. North America Coronary artery disease Market By Region, From 2018-2023 (USD billion)                                                              
  9. North America Hypertension Market By Region, From 2018-2023 (USD billion)                                                   
  10. North America Hyperlipidaemia Market By Region, From 2018-2023 (USD billion)                                                             
  11. North America Thrombosis Market By Region, From 2018-2023 (USD billion)                                                      
  12. North America Cardiac failure diseases Market By Region, From 2018-2023 (USD billion)                                               
  13. North America Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                    
  14. North America Monotherapies Market By Region, From 2018-2023 (USD billion)                                                               
  15. North America Combination Therapies Market By Region, From 2018-2023 (USD billion)                                               
  16. United States Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                            
  17. United States Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                      
  18. Canada Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                        
  19. Canada Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                  
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.